Abstract
Background and objectives: Obesity is a state of chronic low-grade inflammation, which may improve with n-3 long-chain polyunsaturated fatty acid (LCPUFA) treatment in populations with low n-3 LCPUFA status. Inflammation reduces iron bioavailability by increasing hepcidin concentrations, leading to iron sequestration in macrophages and reduced intestinal iron absorption. Therefore, the objective of this study was to investigate the effects of n-3 LCPUFA supplementation on inflammatory markers and fractional iron absorption in overweight and obese individuals with chronic low-grade inflammation and a low n-3 LCPUFA status. Methods: In a single group stable iron isotope study, overweight and obese women of African descent (n = 33) with a BMI ≥ 28 kg/m2, C-reactive protein (CRP) between 2 and 20 mg/L, Hb ≥ 11 g/dL and n-3 index < 6% were supplemented with ~2 g DHA/EPA daily for 15 weeks. Inflammatory markers, hepcidin, iron status indices and erythrocyte total phospholipid fatty acid composition (% of total fatty acids) were measured at baseline and endpoint. Fractional iron absorption (%) was determined by measuring erythrocyte incorporation of isotopically labelled iron (58Fe) at the baseline and endpoint. Sample analysis is ongoing and the results, including fractional iron absorption, for all participants will be available by the time of the conference. Results: Thirty women completed the study. Their mean BMI at baseline was 36.7 ± 8.08 kg/m2,they had a mean n-3 index of 4.57 ± 0.83%, and median (95% CI) fractional iron absorption (FIA) was 11.8% (7.1–20.1). The n-3 index increased to 6.59 ± 0.82% (p < 0.001)) but there was no change in FIA (9.7% (5.1–15.8), p = 0.962) Inflammatory status at baseline was characterized by a median (IQR) CRP of 4.15 (1.50–7.90) mg/L and alpha-1-glycoprotein of 0.99 (0.76–1.11) g/L and there was no change at endpoint. Median serum ferritin was 28.1 (12.3–71.6) µg/L and soluble transferrin receptor was 5.9 (4.8–7.1) mg/L, resulting in body iron stores of 4.80 (0.85–6.92) mg/kg body weight. Discussion: The overweight and obese women in this study had a low n-3 index and high inflammatory status at baseline. Despite improvement of the n-3 index after 15-week supplementation, inflammatory markers and FIA did not improve at endpoint. To understand whether the improvement of the n-3 index was insufficient or the supplement dose too low requires further investigation.
Author Contributions
Conceptualization, I.H.-A., L.M., M.S. and J.B.; investigation, L.M., M.A.U. and L.Z.; data curation, M.A.U.; writing—original draft preparation, I.H.-A.; writing—review and editing, J.B.; project administration, L.M. and A.L.; funding acquisition, A.L. and I.H-A. All authors have read and agreed to the published version of the manuscript.
Funding
This project was funded by the Swiss-African Research Cooperation and the Foundation for the encouragement of Nutrition Research in Switzerland.
Institutional Review Board Statement
The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of North West University, Potchefstroom, South Africa and of ETH Zurich, Switzerland.
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study.
Data Availability Statement
After publication of the main results of the study data can be made available upon approval of a request.
Conflicts of Interest
The authors declare no conflict of interest.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).